vimarsana.com
Home
Live Updates
FDA Grants ODD to Cevidoplenib for the Treatment of Immune T
FDA Grants ODD to Cevidoplenib for the Treatment of Immune T
FDA Grants ODD to Cevidoplenib for the Treatment of Immune Thrombocytopenia
The orphan drug designation (ODD) comes after positive results from a phase 2 trial that showed cevidoplenib improved platelet counts by 63.6% and 40.9% in 2 different dose groups.
Related Keywords
,
Taeyoung Yoon ,
Oscotec Inc ,
Patients With Persistent ,
Chronic Immune Thrombocytopenia ,
Orphan Drug Designation ,
Oscotec Announces Topline Results ,